

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/021727 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) A61K 47/68 (2017.01)
A61K 47/55 (2017.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/070651

(22) International Filing Date:

21 July 2024 (21.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23187008.0 21 July 2023 (21.07.2023) EP

(71) Applicant: **SIMRIS BIOLOGICS GMBH** [DE/DE];
Magnusstr. 11, 12489 Berlin (DE).

(72) Inventors: **NIEDERMEYER, Timo**; Willy-Lohmann-Str.
11, 06114 Halle (DE). **SCHUSTER, Sabine**; Am Wal-
drand 23, 06120 Halle (DE). **ENKE, Dan**; Rohrbachstr. 5A,

12307 Berlin (DE). **ENKE, Heike**; Rohrbachstr. 5A, 12307
Berlin (DE).

(74) Agent: **ANDRESEN, Heiko**; HANSEPATENT Patentan-
wälte Andresen Scholz PartG mbB, Poststr. 33, 20354 Ham-
burg (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ORGANIC CYTOTOXIN OLIGOMERS AND USES THEREOF AS A PAYLOAD IN ANTIBODY-DRUG CONJU-
GATES




Fig. 12

(57) Abstract: A pharmaceutical cytotoxin oligomer is provided. The pharmaceutical cytotoxin oligomer comprises a first organic cytotoxin entity, at least a second organic cytotoxin entity, and a crosslinking entity forming a covalent linkage between the first organic cytotoxin entity and the second organic cytotoxin entity, wherein a monomer of the first organic cytotoxin entity and a monomer of the second organic cytotoxin entity each exerts a cytotoxic effect on a target cell by being actively transported into the target cell by a transporter protein of the target cell, and/or by inhibiting an intracellular enzyme of the target cell. The covalent linkage between the first organic cytotoxin entity and the second organic cytotoxin entity is substantially resistant to cleavage under physiological conditions.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))